SI
ALXN

Scharf Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Scharf Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-457,897
Closed -$84.1M – 51
2021
Q2 		$84.1M Sell
457,897
-83,762
-15% -$14.4M 2.55% 20
2021
Q1 		$82.8M Buy
541,659
+2,900
+0.5% +$449K 2.87% 20
2020
Q4 		$84.2M Sell
538,759
-10,965
-2% -$1.41M 3.17% 18
2020
Q3 		$62.9M Sell
549,724
-22,473
-4% -$2.42M 2.71% 18
2020
Q2 		$64.2M Buy
572,197
+2,852
+0.5% +$303K 2.88% 17
2020
Q1 		$51.1M Buy
+569,345
New +$55.9M 2.56% 20

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Scharf Investments's ALXN Position: Q3 2021 in Review

Scharf Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 457,897 shares — an estimated $84.1M sold.

Scharf Investments first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $84.2M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Scharf Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Scharf Investments sold 457,897 Alexion Pharmaceuticals shares in Q3 2021, an estimated $84.1M.
  • Scharf Investments first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Scharf Investments's Alexion Pharmaceuticals position peaked at $84.2M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Scharf Investments's 13F filing for Q3 2021, filed 14 Oct 2021.